

# Mangalam Drugs and Organics Limited



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

**REF: MDOL/CS-SE/2024- 25/031**

**November 14, 2024**

**To,**

Listing Department

**BSE Ltd**

1<sup>st</sup> Floor, New Trade Wing,

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai - 400 001.

**Scrip Code: 532637**

Listing Department

**National Stock Exchange of India Limited**

"Exchange Plaza", 5<sup>th</sup> Floor,

Plot No. C-1, Block G,

Bandra - Kurla Complex,

Bandra(E), Mumbai - 400 051

**Symbol: MANGALAM**

**Sub: Outcome of the Board Meeting held on Thursday, November 14, 2024**

**Ref: Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations) read with SEBI Circular CIR / CFD / CMD /4 /2015 dated September 09, 2015**

Dear Sir / Madam,

With respect to the captioned subject and mentioned reference, we are pleased to inform that the Board of Directors of the Company, in their meeting held today i.e., Thursday, November 14, 2024 has *inter-alia* transacted, considered and approved the following business:

- The Un-Audited Financial Results (Standalone and Consolidated) along with the Limited Review Report of the Company for the quarter ended September 30, 2024 pursuant to Regulation 33 of the SEBI LODR Regulations. (A copy of the said results, notes thereto and Limited Review Report is annexed hereto and marked as Annexure I.)

Pursuant to Regulation 33(3)(d) of the Listing Regulations, we hereby declare that in respect of the Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended September 30, 2024, the statutory Auditors have not expressed any modified opinion(s) in their Audit Reports.

The Board meeting commenced at 5:00 P.M. and concluded at 6:45 P.M.

We request you to take the same on your records.

Thanking You,

Yours faithfully,

**For Mangalam Drugs & Organics Limited**

**Govardhan M. Dhoot**

Chairman & Managing Director

**DIN: 01240086**



## MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



Standalone Statement of Assets and Liabilities		
	Rs. in Lakhs	
	As at 30.09.2024 Unaudited	As at 31.03.2024 Audited
<b>ASSETS</b>		
<b>A. Non-current Assets</b>		
(a) Property, Plant and Equipment	10127.89	10383.00
(b) Right to use assets	2207.79	2269.40
(c) Capital Work-In-Progress	0.00	0.00
(d) Other Intangible Assets	1917.08	2078.17
(e) Intangible Assets Under Development	1118.45	773.65
(f) Financial Assets		
(i) Investments	3.45	3.45
(ii) Other Financial Assets	9.00	9.00
(g) Other Non-current Assets	190.11	219.78
<b>Total Non-current Assets (A)</b>	<b>15573.77</b>	<b>15,736.45</b>
<b>B. Current Assets</b>		
(a) Inventories	14295.26	12363.97
(b) Financial Assets		
(i) Trade Receivables	2563.84	2794.42
(ii) Cash and Cash Equivalents	587.92	99.90
(iii) Bank Balance other than Cash and Cash Equivalents	0.76	0.76
(iv) Loans	110.21	116.54
(v) Other Financial Assets	3440.32	2868.79
(c) Other Current Assets	1475.11	1733.62
<b>Total Current Assets (B)</b>	<b>22473.42</b>	<b>19,978.00</b>
<b>TOTAL ASSETS (A + B)</b>	<b>38047.19</b>	<b>35,714.45</b>
<b>EQUITY AND LIABILITIES</b>		
<b>A. Equity</b>		
(a) Equity Share Capital	1582.82	1582.82
(b) Other Equity	13161.02	12651.95
<b>Total Equity (A)</b>	<b>14743.84</b>	<b>14,234.77</b>
<b>B. Non-Current Liability</b>		
(a) Financial Liabilities		
i) Borrowings	922.00	1335.41
ii) Lease Liabilities	307.47	513.38
iii) Other Financial Liabilities	0.05	0.05
(b) Deferred Tax Liabilities (Net)	837.10	1208.59
(c) Other Non-Current Liabilities	310.48	327.15
<b>Total Non-current Liabilities (B)</b>	<b>2377.10</b>	<b>3,384.58</b>
<b>C. Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	6551.12	7459.58
(ii) Lease Liabilities	519.56	540.88
(iii) Trade Payables		
Total Outstanding dues to Micro and small enterprises	1025.07	825.88
Total Outstanding dues of creditors other than micro and small enterprises	9838.82	7479.61
(iv) Other Financial Liabilities	1643.76	849.88
(b) Provisions	347.97	98.96
(c) current tax liabilities	28.88	0.00
(d) Other Current Liabilities	971.07	840.31
<b>Total Current Liabilities (C)</b>	<b>20926.25</b>	<b>18,095.10</b>
<b>TOTAL EQUITY AND LIABILITIES (A + B + C)</b>	<b>38047.19</b>	<b>35,714.45</b>





MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended on September 30, 2024

Sr.No	Particulars	Quarter Ended			Half Year Ended		(Rs. In Lakhs)
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income from Operations</b>						
	(a) Net Sales and Services from Operations	7,975.17	7,649.41	8,136.64	15,624.58	16,836.98	36,735.35
	(b) Other Operating Income	19.17	4.21	18.91	23.38	65.37	124.12
	<b>Total Income from Operations (net) (a+b)</b>	<b>7,994.34</b>	<b>7,653.62</b>	<b>8,155.55</b>	<b>15,647.96</b>	<b>16,902.35</b>	<b>36,859.47</b>
2	<b>Expenses</b>						
	(a) Cost of Materials Consumed	4,340.21	4,053.44	6,689.54	8,393.65	12,655.74	22,475.54
	(b) Purchase of Stock in trade	234.89	607.28	64.19	842.17	64.43	1065.35
	(c) Changes in Inventories of Finished Goods, Work In Progress and Stock-in-trade	(508.72)	(619.80)	(1,681.92)	(1,128.52)	(1,061.20)	910.33
	(d) Employee Benefits Expenses	1,017.77	956.85	1,010.83	1,974.62	1,899.36	3,907.13
	(e) Depreciation and amortization expenses	396.75	387.34	373.01	784.09	714.87	1,463.22
	(f) Other Expenses	2,040.87	1,837.23	1,853.67	3,878.10	3,472.23	6,781.75
	<b>Total Expenses (a to f)</b>	<b>7,521.77</b>	<b>7,222.34</b>	<b>8,309.32</b>	<b>14,744.11</b>	<b>17,745.43</b>	<b>36,583.32</b>
3	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>472.57</b>	<b>431.28</b>	<b>(153.77)</b>	<b>903.85</b>	<b>(843.08)</b>	<b>276.15</b>
4	Other Income	13.59	2.02	2.89	15.61	4.85	9.80
5	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)</b>	<b>486.16</b>	<b>433.30</b>	<b>(150.88)</b>	<b>919.46</b>	<b>(838.23)</b>	<b>285.95</b>
6	Finance costs (net)	366.56	374.83	324.48	741.39	665.67	1,391.89
7	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>119.60</b>	<b>58.47</b>	<b>(475.36)</b>	<b>178.07</b>	<b>(1,503.90)</b>	<b>(1,105.74)</b>
8	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
9	<b>Profit/(Loss) from ordinary activities before tax (7-8)</b>	<b>119.60</b>	<b>58.47</b>	<b>(475.36)</b>	<b>178.07</b>	<b>(1,503.90)</b>	<b>(1,105.74)</b>
10	<b>Tax Expenses</b>						
	(a) Current Tax	1.00	0.00	10.61	1.00	10.61	19.15
	(b) Deferred Tax	(150.00)	(210.00)	(130.00)	(360.00)	(205.00)	(220.00)
	<b>Total Tax Expenses (a+b)</b>	<b>(149.00)</b>	<b>(210.00)</b>	<b>(119.39)</b>	<b>(359.00)</b>	<b>(194.39)</b>	<b>(200.85)</b>
11	<b>Net Profit(+)/Loss(-) from ordinary activities after tax (9-10)</b>	<b>268.60</b>	<b>268.47</b>	<b>(355.97)</b>	<b>537.07</b>	<b>(1,309.51)</b>	<b>(904.89)</b>
12	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
13	<b>Net Profit(+)/Loss (-) for the period(11-12)</b>	<b>268.60</b>	<b>268.47</b>	<b>(355.97)</b>	<b>537.07</b>	<b>(1,309.51)</b>	<b>(904.89)</b>
14	Share of Profit / (Loss) of associates						
15	Minority Interest						
16	<b>Net Profit / (Loss) after taxes, minority interest and share of profit / -(loss) of associates (13-14-15)</b>	<b>268.60</b>	<b>268.47</b>	<b>(355.97)</b>	<b>537.07</b>	<b>(1,309.51)</b>	<b>(904.89)</b>
17	Other Comprehensive Income not reclassified into Profit and loss account (Net of Taxes)	(14.00)	(13.99)	3.12	(27.99)	6.24	(55.97)
18	<b>Total Comprehensive Income (16+17)</b>	<b>254.60</b>	<b>254.48</b>	<b>(352.85)</b>	<b>509.08</b>	<b>(1,303.27)</b>	<b>(960.86)</b>
19	Paid-up Equity Share Capital (Face value of Rs 10/- per share)	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82
20	Reserve excluding Revaluation Reverses as per balance sheet of previous accounting year						12,651.43
20	<b>Earnings Per Share (EPS) (of Rs 10/-each not annualised):</b>						
	(a) Basic	1.70	1.70	(2.25)	3.39	(8.27)	(5.72)
	(b) Diluted	1.70	1.70	(2.25)	3.39	(8.27)	(5.72)





MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413


Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



Standalone Cash Flow Statement for the period ended September 30, 2024

(Rs. In Lakhs)

Particulars	For the Period ended September 30, 2024 Unaudited	For the Period ended March 31, 2024 Audited
<b>A. Cash flow from operating activities</b>		
Net profit before tax and extra ordinary items.	178.07	(1,105.74)
<b>Add / (Less) :</b>		
Depreciation & amortisation	784.09	1,463.22
Interest expenses (net)	741.39	1,391.69
Dividend Income	(0.04)	(0.04)
(Gain)/loss on sale of fixed assets	(13.22)	5.22
Remeasurements of the defined benefit plans	(39.49)	(78.97)
<b>Operating profit before working capital changes</b>	<b>1,650.80</b>	<b>1,675.38</b>
<b>Adjustment for :</b>		
(Increase)/decrease in short term loans and advances	6.33	(111.99)
(Increase)/decrease in other current assets	(313.02)	(2,784.81)
(Increase)/decrease in trade receivables	230.58	1,858.87
(Increase)/decrease in inventory	(1,931.28)	1,382.67
(Increase)/decrease in other non-current assets	29.66	57.60
Increase/(decrease) in trade payables	2,558.40	(1,237.31)
Increase/(decrease) in other current liabilities	130.75	487.97
Increase/(decrease) in provisions	1,071.77	150.90
Increase/(decrease) in current lease liabilities	(21.32)	(180.61)
Increase/(decrease) in non-current liabilities	(16.67)	97.81
Increase/(decrease) in non current lease liabilities	(205.91)	(160.52)
Increase/(decrease) in deposits	0.00	-
	<b>1,539.29</b>	<b>(439.41)</b>
<b>Cash generated from operations</b>	<b>3,190.09</b>	<b>1,235.96</b>
<b>Add / ( Less) :</b>		
Income Tax (Paid)/ Refund	(1.00)	(19.15)
<b>Net cash from operating activities</b>	<b>3,189.09</b>	<b>1,216.81</b>
<b>B. Cash flow from investing activities :</b>		
Purchase of fixed assets including Capital WIP	(665.60)	(1,791.62)
Sale of fixed assets	27.75	4.10
Sale/(Purchase) of investments	-	(3.02)
Divided Income	0.04	0.04
<b>Net cash from investing activities</b>	<b>(637.81)</b>	<b>(1,790.50)</b>
<b>C. Cash flow from financing activities :</b>		
Proceeds/(repayment) of short term borrowing	(908.46)	2,502.87
Proceeds/(repayment) of long term borrowing	(413.41)	(541.22)
Interest Paid (net)	(741.39)	(1,391.69)
<b>Net cash used in financing activities</b>	<b>(2,063.26)</b>	<b>569.96</b>
<b>Net increase / (decrease) in cash and cash equivalents</b>	<b>488.02</b>	<b>(3.73)</b>
<b>Cash and cash equivalents - opening balance</b>	<b>99.90</b>	<b>103.61</b>
<b>Cash and cash equivalents - closing balance</b>	<b>587.92</b>	<b>99.90</b>
<b>Details of cash and cash equivalent at the end of the Period / Year</b>		
- Cash in hand	23.43	6.70
- Balance in current and deposit accounts	564.49	93.20
<b>Total</b>	<b>587.92</b>	<b>99.90</b>





**MANGALAM DRUGS AND ORGANICS LIMITED**

CIN - L24230MH1972PLC116413



Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.

**Notes :**

- 1 The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter.
- 2 The above audited standalone financial results of the Company for the Quarter and Half year ended have been reviewed by the Audit Committee and thereafter, approved and taken on record by the Board of Directors of the Company (Mangalam Drugs and Organics Limited) at their meeting held on November 14, 2024.
- 3 The Company's business activity falls within a single reportable Business Segment Viz. "Manufacturing of Bulk Drugs".
- 4 The figures for the quarter ended 30th September, 2024 are the balancing figures between the figures in respect of the half year ended 30th September 2024 and the unaudited published figures for quarter ended 30th June 2024.
- 5 The Board of Directors of the Company at its meeting held on March 15, 2024 had considered and approved the scheme of Merger by Absorption of Mangalam Laboratories Private Limited ("First Transferor Company") a Wholly Owned Subsidiary and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) ("Second Transferor Company") with Mangalam Drugs and Organics Limited ("Transferee Company") and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to the necessary statutory and regulatory approvals including the approvals of Hon'ble National Company Law Tribunal, the shareholders and creditors of each of the companies. As on date, the Scheme is pending for disposal at both the Stock Exchanges who shall issue No Objection Certificate under Regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- 6 The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods under presentation.

Place: Mumbai

Date: 14 th November ,2024

On behalf of Board of Directors  
For Mangalam Drugs and Organics Limited  
Shri Govardhan M. Dhoot  
Chairman and Managing Director  
DIN:01240086





**Limited Review Report on Unaudited Standalone Financial Results of Mangalam Drugs and Organics Limited for the Quarter and Half year ended on 30<sup>th</sup> September, 2024 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10<sup>th</sup> August 2021 as amended.**

**The Board of Directors,**  
Mangalam Drugs and Organics Limited,

1. We have reviewed the accompanying statement of unaudited financial results of **Mangalam Drugs and Organics Limited** (the "Company") for the quarter and half year ended on September 30, 2024 (the "Statement") attached herewith, being submitted by the Company, pursuant to the requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.




**4. Conclusion:**

Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai  
Date: November 14, 2024



**For V.S. SOMANI & Co.,**  
*Chartered Accountants*  
*Firm Registration No. 117589W*

  
**CA Vidyadhar Somani**

*Proprietor*  
Membership No. 102664  
UDIN No. 241026648 KEJFY1918




**MANGALAM DRUGS AND ORGANICS LIMITED**  
CIN - L24230MH1972PLC116413



Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.

Consolidated Statement of Assets and Liabilities		Rs. in Lakhs	
	As at 30.09.2024 Unaudited	As at 31.03.2024 Audited	
<b>ASSETS</b>			
<b>A. Non-current Assets</b>			
(a) Property, Plant and Equipment	10,871.07	10,419.26	
(b) Right to use assets	2,207.79	2,269.41	
(c) Capital Work-In-Progress	-	-	
(d) Other Intangible Assets	1,917.08	2,078.17	
(e) Intangible Assets Under Development	1,118.45	773.65	
(f) Financial Assets			
(i) Investments	0.44	0.44	
(ii) Other Financial Assets	9.15	9.28	
(g) Other Non-current Assets	190.11	219.78	
<b>Total Non-current Assets (A)</b>	<b>16,314.09</b>	<b>15,769.99</b>	
<b>B. Current Assets</b>			
(a) Inventories	14,295.26	12,363.98	
(b) Financial Assets			
(i) Trade Receivables	2,563.84	2,794.42	
(ii) Cash and Cash Equivalents	607.85	117.96	
(iii) Bank Balance other than Cash and Cash Equivalents	0.76	0.76	
(iv) Loans	110.21	116.54	
(v) Other Financial Assets	1,043.56	472.55	
(c) Other Current Assets	1,475.50	1,733.80	
<b>Total Current Assets (B)</b>	<b>20,096.98</b>	<b>17,600.01</b>	
<b>TOTAL ASSETS (A + B)</b>	<b>36,411.07</b>	<b>33,370.00</b>	
<b>EQUITY AND LIABILITIES</b>			
<b>A. Equity</b>			
(a) Equity Share Capital	1,582.82	1,582.82	
(b) Other Equity	13,214.04	11,996.47	
<b>Total Equity (A)</b>	<b>14,796.86</b>	<b>13,579.29</b>	
<b>B. Non-Current Liability</b>			
(a) Financial Liabilities			
i) Borrowings	922.00	1,335.41	
ii) Lease Liabilities	307.47	513.38	
ii) Other Financial Liabilities	0.05	0.05	
(b) Deferred Tax Liabilities (Net)	837.10	1,208.59	
(c) Other Non-Current Liabilities	310.48	327.15	
<b>Total Non-current Liabilities (B)</b>	<b>2,377.10</b>	<b>3,384.58</b>	
<b>C. Current Liabilities</b>			
(a) Financial Liabilities			
(i) Borrowings	6,551.12	7,459.58	
(ii) Lease Liabilities	519.57	540.89	
(iii) Trade Payables			
Total Outstanding dues to Micro and small enterprises	1,025.07	825.89	
Total Outstanding dues of creditors other than micro and small	8,149.53	5,790.32	
(iv) Other Financial Liabilities (other than those specified in item (c))	1,643.76	849.88	
(b) Provisions	347.97	98.96	
(c) current tax liabilities	28.88	-	
(d) Other Current Liabilities	971.21	840.61	
<b>Total Current Liabilities (C)</b>	<b>19,237.11</b>	<b>16,406.13</b>	
<b>TOTAL EQUITY AND LIABILITIES (A + B + C)</b>	<b>36,411.07</b>	<b>33,370.00</b>	





MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLCL16413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



Sr.No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
							(Rs. In Lakhs)
<b>A) Part-1 Consolidated Statement of Unaudited Financial Results for the Quarter and Half Year ended on September 30, 2024</b>							
1	<b>Income from Operations</b>						
	(a) Net Sales and Services from Operations	7,975.17	7,649.41	-	15,624.58	16,838.99	36,735.36
	(b) Other Operating Income	19.17	4.21	-	23.38	65.37	124.12
	<b>Total Income from Operations (net) (a+b)</b>	<b>7,994.34</b>	<b>7,653.62</b>	<b>-</b>	<b>15,647.96</b>	<b>16,902.36</b>	<b>36,859.48</b>
2	<b>Expenses</b>						
	(a) Cost of Materials Consumed	4,340.21	4,053.44	-	8,393.65	12,655.74	22,475.54
	(b) Purchase of Stock in trade	234.89	607.28	-	842.17	64.43	1,065.35
	(c) Changes in Inventories of, Finished Goods, and Work In Progress and Stock-in-trade	(508.72)	(619.80)	-	(1,120.52)	(1,061.20)	910.33
	(d) Employee Benefits Expenses	1,017.77	956.85	-	1,974.62	1,899.36	3,907.13
	(e) Depreciation and amortization expenses	397.49	387.80	-	785.29	715.80	1,465.08
	(f) Other Expenses	2,039.74	1,836.78	-	3,670.52	3,473.07	6,761.47
	<b>Total Expenses (a to f)</b>	<b>7,521.38</b>	<b>7,222.35</b>	<b>-</b>	<b>14,743.73</b>	<b>17,748.00</b>	<b>36,584.90</b>
3	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>472.96</b>	<b>431.27</b>	<b>-</b>	<b>904.23</b>	<b>(845.64)</b>	<b>274.58</b>
4	Other Income	13.59	2.02	-	15.61	6.95	9.80
5	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)</b>	<b>486.55</b>	<b>433.29</b>	<b>-</b>	<b>919.84</b>	<b>(838.69)</b>	<b>284.38</b>
6	Finance costs (net)	366.56	374.83	-	741.39	665.67	1,391.70
7	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>119.99</b>	<b>58.46</b>	<b>-</b>	<b>178.45</b>	<b>(1,504.36)</b>	<b>(1,107.32)</b>
8	Exceptional items	-	-	-	-	-	-
9	<b>Profit/(Loss) from ordinary activities before tax (7-8)</b>	<b>119.99</b>	<b>58.46</b>	<b>-</b>	<b>178.45</b>	<b>(1,504.36)</b>	<b>(1,107.32)</b>
10	Tax Expenses						
	Current Tax	1.00	-	-	1.00	10.61	19.85
	Deferred Tax	(150.00)	(210.00)	-	(360.00)	(205.00)	(220.00)
	<b>Total Tax Expenses (a+b)</b>	<b>(149.00)</b>	<b>(210.00)</b>	<b>-</b>	<b>(359.00)</b>	<b>(194.39)</b>	<b>(200.15)</b>
11	<b>Net Profit(+)/Loss(-) from ordinary activities after tax (9-10)</b>	<b>268.99</b>	<b>268.46</b>	<b>-</b>	<b>537.45</b>	<b>(1,309.97)</b>	<b>(907.17)</b>
12	Extraordinary Items	-	-	-	-	-	-
13	<b>Net Profit(+)/Loss (-) for the period(11-12)</b>	<b>268.99</b>	<b>268.46</b>	<b>-</b>	<b>537.45</b>	<b>(1,309.97)</b>	<b>(907.17)</b>
14	Share of Profit / (Loss) of associates	-	-	-	-	-	-
15	Minority Interest	-	-	-	-	-	-
16	<b>Net Profit / (Loss) after taxes, minority interest and share of profit / -(loss) of associates (13-14-15)</b>	<b>268.99</b>	<b>268.46</b>	<b>-</b>	<b>537.45</b>	<b>(1,309.97)</b>	<b>(907.17)</b>
17	Other Comprehensive income not reclassified into Profit and loss account (Net of Taxes)	694.12	(13.99)	-	680.13	6.24	(55.97)
	<b>Total Comprehensive Income (16+17)</b>	<b>963.11</b>	<b>254.47</b>	<b>-</b>	<b>1,217.58</b>	<b>(1,303.73)</b>	<b>(963.14)</b>
18	Paid-up Equity Share Capital (Face value of Rs 10/- per share)	1,582.82	1,582.82	-	1,582.82	1,582.82	1,582.82
19	Reserve excluding Revaluation Reverses as per balance sheet of previous accounting year	-	-	-	-	-	11,996.46
20	<b>Earnings Per Share (EPS) (of Rs 10/-each not annualised):</b>						
	(a) Basic	1.70	1.70	-	3.40	(8.28)	(5.73)
	(b) Diluted	1.70	1.70	-	3.40	(8.28)	(5.73)





**MANGALAM DRUGS AND ORGANICS LIMITED**

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



**Consolidated Cash Flow Statement For the Period Ended September 30, 2024**


(Rs. In Lakhs)

Particulars	For the Period September 30, 2024 Unaudited	For the Period September 30, 2023 to March 31, 2024 Audited
<b>A. Cash flow from operating activities</b>		
Net profit before tax and extra ordinary items.	178.45	397.05
<b>Add / (Less) :</b>		
Depreciation & amortisation	785.29	749.28
Interest expenses (net)	741.39	726.03
Dividend Income	(0.04)	(0.04)
(Gain)/loss on sale of fixed assets	(13.22)	7.03
Remeasurements of the defined benefit plans	(39.49)	(87.77)
<b>Operating profit before working capital changes</b>	<b>1,652.38</b>	<b>1,791.57</b>
<b>Adjustment for :</b>		
(Increase)/decrease in short term loans and advances	6.33	(106.69)
(Increase)/decrease in other current assets	(312.71)	1,242.61
(Increase)/decrease in trade receivables	230.58	104.67
(Increase)/decrease in inventory	(1,931.29)	1,688.76
(Increase)/decrease in other non-current assets	29.79	56.83
Increase/(decrease) in Other Equity	-	-
Increase/(decrease) in trade payables	2,558.40	(1,990.42)
Increase/(decrease) in other current liabilities	130.61	(2,325.67)
Increase/(decrease) in provisions	1,071.77	124.80
Increase/(decrease) in current lease liabilities	(21.32)	(137.28)
Increase/(decrease) in non-current liabilities	(16.67)	97.80
Increase/(decrease) in deposits	-	-
Increase/(decrease) in non current lease liabilities	(205.91)	(146.49)
	<b>1,539.58</b>	<b>(1,391.09)</b>
<b>Cash generated from operations</b>	<b>3,191.96</b>	<b>400.49</b>
<b>Add / ( Less) :</b>		
Income Tax (Paid)/ Refund	(1.00)	(9.24)
<b>Net cash from operating activities</b>	<b>3,190.96</b>	<b>391.25</b>
<b>B. Cash flow from investing activities :</b>		
Purchase of fixed assets including Capital WIP	(665.60)	(1,183.27)
Sale of fixed assets	27.75	0.50
Sale/(Purchase) of investments	-	(0.01)
Divided Income	0.04	0.04
<b>Net cash from investing activities</b>	<b>(637.81)</b>	<b>(1,182.74)</b>
<b>C. Cash flow from financing activities :</b>		
Proceeds/(repayment) of short term borrowing	(908.46)	1,694.01
Proceeds/(repayment) of long term borrowing	(413.41)	(445.32)
Interest Paid (net)	(741.39)	(726.03)
Dividend paid	-	-
Issue of Share	-	-
<b>Net cash used in financing activities</b>	<b>(2,063.26)</b>	<b>522.67</b>
<b>Net increase / (decrease) in cash and cash equivalents</b>	<b>489.89</b>	<b>(268.82)</b>
<b>Cash and cash equivalents - opening balance</b>	<b>117.96</b>	<b>386.78</b>
<b>Cash and cash equivalents - closing balance</b>	<b>607.85</b>	<b>117.96</b>
<b>Details of cash and cash equivalent at the end of the Period / Year</b>		
- Cash in hand	23.43	6.71
- Balance in current and fix deposit accounts	584.42	111.25
<b>Total</b>	<b>607.85</b>	<b>117.96</b>





**MANGALAM DRUGS AND ORGANICS LIMITED****CIN - L24230MH1972PLC116413****Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.****Notes :**

1	The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter.
2	The above audited Consolidated financial results of the Company for the Quarter and half year ended have been reviewed by the Audit Committee and thereafter, approved and taken on record by the Board of Directors of the Company (Mangalam Drugs and Organics Limited) at their meeting held on November 14, 2024.
3	The Company's business activity falls within a single reportable Business Segment Viz. "Manufacturing of Bulk Drugs".
4	The figures for the quarter ended 30th September, 2024 are the balancing figures between the figures in respect of the half year ended 30th September 2024 and the unaudited published figures for quarter ended 30th June 2024.
5	Consolidated results includes results of Mangalam Laboratories Private Limited, a Wholly Owned Subsidiary (WOS) for the purpose of Consolidated results.
6	As on September 30, 2023 the Company has acquired 3010 Equity shares of Mangalam Laboratories Private Limited of Rs. 100 each, which is a wholly owned subsidiary of the Company. The WOS is not a material subsidiary of the Company on acquisition.
7	Since the Company, has acquired control on September 30, 2023 hence consolidation is applicable only from September 30, 2023. Figures for the quarter ended September 30, 2023 in respect of Statement of profit & loss account is not applicable to the Company.
8	The Board of Directors of the Company at its meeting held on March 15, 2024 had considered and approved the scheme of Merger by Absorption of Mangalam Laboratories Private Limited ("First Transferor Company") a Wholly Owned Subsidiary and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) ("Second Transferor Company") with Mangalam Drugs and Organics Limited ("Transferee Company") and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to the necessary statutory and regulatory approvals including the approvals of Hon'ble National Company Law Tribunal, the shareholders and creditors of each of the companies. As on date, the Scheme is pending for disposal at both Stock Exchanges who shall issue No Objection Certificate under Regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
9	The figures for the previous periods have been regrouped wherever necessary to conform to the current periods under presentation.
<p>On behalf of Board of Directors For Mangalam Drugs and Organics Limited</p>  <p>Shri Govardhan M. Dhoot Chairman and Managing Director DIN:01240086</p>	
Place: Mumbai Date: November 14, 2024	







**Limited Review Report on Unaudited Consolidated Financial Results of Mangalam Drugs and Organics Limited for the Quarter and Half year ended on 30<sup>th</sup>September, 2024 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10<sup>th</sup>August 2021 as amended.**

**To the Board of Directors,**  
Mangalam Drugs and Organics Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of **Mangalam Drugs and Organics Limited** (hereinafter referred to as "the Parent"), its subsidiary (the Parent and its subsidiary together referred to as "the Group") and its share of the net profit after tax and total comprehensive income of its subsidiary for the half year ended from 1<sup>st</sup>April 2024 to 30<sup>th</sup>September 2024 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10<sup>th</sup>August 2021.
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10<sup>th</sup>August 2021. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.





4. The statement includes the results of the Mangalam Laboratories Private Limited a subsidiary.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10<sup>th</sup> August 2021, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of a subsidiary included in the Statement, whose interim financial results reflects total assets (before consolidation adjustments) of Rs. 2,452.91 Lakhs as at 30<sup>th</sup> September, 2024 and total revenues (before consolidation adjustments) of Rs. 2.60 Lakhs total net Profit after tax and total comprehensive income (before consolidation adjustments) of Rs. 708.49 Lakhs for the half year ended 30<sup>th</sup> September, and cash outflows (net) (before consolidation adjustments) of Rs. 1.87 Lakhs for the period from 1<sup>st</sup> April, 2024 to 30<sup>th</sup> September, 2024 as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

**For V.S. SOMANI & Co.,**  
*Chartered Accountants*  
Firm Registration No. 117589W



*V.S. Somani*

**C.A. Vidyadhar Somani**  
*Proprietor*

Membership No. 102664

UDIN No. 24102664BKEJFX3844

Place: Mumbai

Date: November 14, 2024